期刊文献+

恶性肿瘤化疗后继发侵袭性肺曲霉菌病的CT表现

A study on the appearance of invasive pulmonary aspergillosis secondary to post-chemotherapy of malignant tumors on CT images
下载PDF
导出
摘要 目的分析恶性肿瘤化疗后继发侵袭性肺曲霉菌病的CT表现,提高对本病的诊断准确性。方法回顾性分析64例化疗后发生肺部侵袭性肺曲霉菌病的恶性肿瘤患者的胸部CT表现,观察肺及肺外病变影像特征。结果 64例均为肺部多发不规则模糊实变影,其中单肺18.75﹪(12/64),双肺81.25﹪(52/64);支气管充气征81.25﹪(52/64),晕征39.06﹪(25/64),空气新月征15.63﹪(10/64);胸腔积液45.31﹪(29/64),胸膜增厚26.56﹪(17/64),肺门淋巴结肿大32.81﹪(21/64),纵隔淋巴结肿大18.75﹪(12/64),心包积液4.69﹪(3/64)。结论肺部曲霉菌感染的CT表现复杂,结合患者临床资料综合分析,能够为恶性肿瘤化疗后继发IPA临床治疗诊断提供依据。 Objective To investigate the the appearance of invasive pulmornary aspergillosis secondary to post-chemotherapy of malignant tumors on CT images, and to improve the diagnostic accuracy. Methods The CT feathers of chest in 64 patients, including pulmonary and extrapulmonary lesions , were retrospectively analyzed. Result Muliple lesions with irregular and fuzzy consolidation were observed in all cases, including unilater lung 18.75 ﹪(12/64) , bilater lung 81.25﹪(52/64) , air bronchogram 81.25﹪(52/64) , halo sign 39.06﹪(25/64) , air-crescent sign 15.63 ﹪(10/64) , pleural effusion 45.31﹪(29/64) , pleural thickness 26.56﹪(17/64) , hilar lymph node enlargement 32.81 ﹪(21/64), mediastinal lymph node enlargement 18.75 ﹪(12/64), pericardial effusion 4.69 ﹪(3/64). Conclusion The appearance of invasive pulmornary aspergillosis on CT images were complex and diverse, and the clinical data should be integrated, to provide a basis for diagnose of IPA secondary to post-chemotherapy of malignant tumors.
出处 《功能与分子医学影像学(电子版)》 2017年第4期1318-1322,共5页 Functional and Molecular Medical Imaging(Electronic Edition)
基金 江西省重点研发计划项目(20161BBG70103)
关键词 侵袭性肺曲霉菌病 恶性肿瘤 化疗 计算机断层摄影 invasive pulmonary aspergillosis chemotherapy malignancy computed tomography
  • 相关文献

参考文献3

二级参考文献33

  • 1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1477
  • 2郭丽娜,汪建新,高强,翁翠莲,李新甫,孙军平.原发性肺淋巴瘤11例临床分析[J].解放军医学杂志,2007,32(10):1069-1071. 被引量:7
  • 3重症患者侵袭性真菌感染诊断与治疗指南(2007)[J].中华内科杂志,2007,46(11):960-966. 被引量:426
  • 4Karrison TG, Maitland ML, Stadler WM, et al. Design of phase II cancer trials using a continuousendpoint of change in tumor size:application to a study of sorafenib and erlotinib in non small-celllung cancer [J]. J Natl Cancer Inst, 2007, 99(19): 1455-1461.
  • 5Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design:application to cytostaticantineoplastic agents [J]. J ClinOncol, 2002, 20(22):4478-4484.
  • 6Ratain MJ, Sargent DJ. Optimising the design of phase II oncology trials: the importance ofrandomisation[J]. Eur J Cancer, 2009, 45(2):275-280.
  • 7Schuetze SM, Baker LH, Benjamin RS, et al. Selection of response criteria for clinical trials ofsarcoma treatment [J]. Oncologist, 2008, 13(suppl 2):32-40.
  • 8WHO handbook for reporting result of cancer treatment. Offset Publication No.48. Geneva (Switzerland): World Health Organization, 1979.
  • 9Ratain MJ, Eckhardt SG. Phase II studies of modem drugs directed against new targets: if you arefazed, too, then resist RECIST [J]. J ClinOncol, 2004, 22(22):4442-4445.
  • 10原发性肺癌诊疗规范(2011年)[S].卫办医政发[2011]22号.

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部